Reaktionsgleichung
[C:1]([C:3]1[CH:4]=[N:5][N:6]2[C:11]([C:12]([F:15])([F:14])[F:13])=[CH:10][C:9]([C:16]3[CH:21]=[CH:20][C:19]([C:22]([F:25])([F:24])[F:23])=[CH:18][CH:17]=3)=[N:8][C:7]=12)#[CH:2].[NH2:26][C:27]1[N:32]=[C:31]([CH3:33])[C:30](Br)=[CH:29][CH:28]=1>>[CH3:33][C:31]1[N:32]=[C:27]([NH2:26])[CH:28]=[CH:29][C:30]=1[C:2]#[C:1][C:3]1[CH:4]=[N:5][N:6]2[C:11]([C:12]([F:14])([F:13])[F:15])=[CH:10][C:9]([C:16]3[CH:21]=[CH:20][C:19]([C:22]([F:25])([F:24])[F:23])=[CH:18][CH:17]=3)=[N:8][C:7]=12Komponenten
3
Versuchsvorschrift
The title compound was prepared from 3-ethynyl-7-trifluoromethyl-5-(4-trifluoromethyl-phenyl)-pyrazolo[1,5-a]pyrimidine (example C.1) (355 mg, 1.0 mmol) and commercially available 6-amino-3-bromo-2-methylpyridine (168 mg, 1.0 mmol) according to general procedure II. Obtained as a dark-red solid (90 mg, 19%). MS (ISP) 462.2 [(M+H)+]; mp 251-254° C.
Quellen und Nachweise
- ORD-Eintrag
- ord-fd1830a865714a9c91e0fd1a665bc9cd
- Quelldatensatz
- uspto-grants-2008_11
- Patentnummer
- US07446113B2
Verknüpfte Notizen
Wird geladen…